Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Nephrology | Urology | Family Medicine
Disease Category: Prostate Cancer
Location: United States, IL
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel.
The purpose of this study is to examine the safety and effectiveness (how well the drug works) of treatment with radiotherapy followed by an investigational compound (a drug that is not currently approved by the United States Food and Drug Administration [FDA] or any other health authority), ipilimumab (also known as MDS-010 or BMS-734016). The effectiveness of ipilimumab will be determined by looking at:
- How many patients respond to treatment with radiotherapy followed by ipilimumab versus radiotherapy alone and how long the response lasts for each of these two treatments
- Survival time of the patients who receive radiotherapy followed by ipilimumab versus radiotherapy alone
- How safe radiotherapy followed by ipilimumab is, and what the side effects are
- How much a patient's level of pain changes when treated with radiotherapy followed by ipilimumab versus radiotherapy alone
- The health-related quality of life patients experience while on radiotherapy followed by ipilimumab versus radiotherapy alone
Please contact Alexian Brothers for more information on participation.
Alexian Brothers Hospital Network
800 Biesterfield Road
Elk Grove Village, IL 60007
If you would like to learn more about participating in this study, please send an email message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these